首页> 美国卫生研究院文献>Antimicrobial Agents and Chemotherapy >Mechanistic studies and biological activity of bioxalomycin alpha 2 a novel antibiotic produced by Streptomyces viridodiastaticus subsp. litoralis LL-31F508.
【2h】

Mechanistic studies and biological activity of bioxalomycin alpha 2 a novel antibiotic produced by Streptomyces viridodiastaticus subsp. litoralis LL-31F508.

机译:沙生霉素链霉菌亚种生产的新型抗生素生物霉素α2的机理研究和生物学活性。 litoralis LL-31F508。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The bioxalomycins, a novel complex of broad-spectrum antibiotics, were isolated from fermentations of Streptomyces viridodiastaticus subsp. "litoralis" LL-31F508. Bioxalomycin alpha 2, the major component of this complex, exhibited antibacterial activity. The MICs ranged from < or = 0.002 to 0.008 micrograms/ml for gram-positive organisms and from 0.50 to 4 micrograms/ml for gram-negative organisms. Bioxalomycin alpha 2 was found to be bactericidal and to inhibit bacterial DNA synthesis preferentially. Bioxalomycin alpha 2 protected mice from a lethal challenge with Staphylococcus aureus Smith. The 50% effective dose of bioxalomycin alpha 2 administered orally was 10 times greater than that when the drug was given subcutaneously or intravenously. These data suggest a stability or bioavailability problem when the compound is administered orally.
机译:Bioxalomycins是一种新型的广谱抗生素复合物,是从Streptomyces viridodiastaticstatic亚种的发酵物中分离出来的。 “ litoralis” LL-31F508。该复合物的主要成分Bioxalomycin alpha 2具有抗菌活性。对于革兰氏阳性生物,MIC的范围为<或= 0.002至0.008微克/ ml,对于革兰氏阴性生物的MIC为0.50至4微克/ ml。发现Bioxalomycin alpha 2具有杀菌作用,可优先抑制细菌DNA的合成。 Bioxalomycin alpha 2保护小鼠免受金黄色葡萄球菌Smith的致命攻击。口服生物沙霉素α2的50%有效剂量比皮下或静脉内给药时大10倍。这些数据表明当口服给药该化合物时存在稳定性或生物利用度问题。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号